Setshaba center for HIV and TB prevention and care
Official title: PHRU-Setshaba Clinical Trials Unit
Funded at Wits Health Consortium (Pty), LTD · NIH-11396707 · Data updated 2026-11-12
A South African clinical research center offers studies of new ways to prevent and treat HIV and tuberculosis for people living in high‑risk communities, including mothers and children.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wits Health Consortium (Pty), LTD NIH-funded |
| Lab location | 1 site (Parktown, South Africa) |
| Project start | February 15, 2007 |
| Project end | November 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $285,660 |
| NIH project number | 3UM1AI069453-20S1 |
| Project ID | NIH-11396707 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people living in the CTU's catchment areas in South Africa who are at risk for or living with HIV (including pregnant people, children, and people with TB co‑infection) or healthy volunteers eligible for prevention or vaccine studies.
✕Less likely to help
People who live outside the CTU's geographic area or whose health concerns are unrelated to HIV or TB are unlikely to benefit from participating.
What this research studies
From my perspective as a potential participant, this program runs multiple research sites in areas with high HIV and TB rates and invites people to join prevention, vaccine, treatment, and observational studies. The team works in informal settlements, maternity units, TB clinics and hospitals to find volunteers, collect health information and biological samples, and deliver study interventions or standard care. The unit supports both pediatric and adult work, and it aims to test approaches ranging from vaccines and biomedical prevention to long‑term management and remission strategies. Participation may involve clinic visits, testing, and follow‑up over time.
Why it matters
Potential benefit: If successful, the work could lower new HIV infections, improve TB control in people with HIV, and lead to better prevention or remission tools for patients.
How similar studies have gone: Previous NIH‑supported programs have shown that antiretroviral treatment and prevention tools like PrEP cut infections, but effective vaccines and durable remission strategies remain limited, so this work builds on progress while targeting unresolved gaps.
Where this research is happening
-
Wits Health Consortium (Pty), LTD
Parktown, South Africa Active
Researchers
- Principal investigator: Gray, Glenda E — Wits Health Consortium (Pty), LTD
- Study coordinator: Gray, Glenda E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.